Abstract

Introduction: Transjugular intrahepatic portosystemic shunt (TIPS) is a fabricated network within the liver developed utilizing inflow portal vein as well as the discharge of the hepatic vein. Throughout current years technological renovations and brand-new understandings of pathophysiology have customized indicators for TIPS. It is typically approved that the transjugular intrahepatic portosystemic shunt treatment has reduced morbidity and death rates better than those of medical shunting. Difficulties are classified per those about transhepatic needle slit, transvenous accessibility to the portal capillary, portal venous cannulation, portosystemic shunting, as well as contrast material. Leaving out hepatic encephalopathy as well as postponed constriction or occlusion of the shunt, much less than 10% can be anticipated for TIPS side-effects. Along with these technological enhancements, standard pathophysiological expertise and hence likewise the indicators for TIPS have actually increased in recent times. This review article talks about the existing state of the understanding of TIPS, technological breakthroughs, problems, and also standards of patient status.

Aim: In this inclusive review, we look into transjugular intrahepatic portosystemic shunts and the management approaches related to this procedure.

Keywords: TIPS; Hepatic Vein; Liver Varices; Portal Vein

References

1. Amesur NB and Novelli P. “Transjugular Intrahepatic Portosystemic Shunt”. Stat Pearls. Treasure Island (FL) (2019).
2. Rossle M. “TIPS: 25 years later”. Journal of Hepatology 59 (2013): 1081-1093.
3. Villanueva C., et al. “Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension”. Hepatology 63 (2016): 197-206.
4. Freedman AM., et al. “Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review”. Radiographics 13 (1993): 1185-1210.
5. De Franchis R and Baveno VIF. “Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension”. Journal of Hepatology 63 (2015): 743-752.
6. Berres ML., et al. “Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt”. Liver International 36 (2016): 386-394.
7. Zahn A., et al. “Budd-Chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt”. BMC Gastroenterology 10 (2010): 25.
8. Boyer TD and Haskal ZJ, “American Association for the Study of Liver D. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009”. Hepatology 51 (2010): 306.
9. David A., et al. “Ultrasonographic guidance for portal vein access during transjugular intrahepatic portosystemic shunt (TIPS) placement”. Diagnostic and Interventional Imaging 100 (2019): 445-453.
10. Khan F., et al. “Timing of Transjugular Intrahepatic Portosystemic Stent-shunt in Budd-Chiari Syndrome: A UK Hepatologist's Perspective”. Journal of Translational Internal Medicine 6 (2018): 97-104.
11. Ripamonti R., et al. “Transjugular intrahepatic portosystemic shunt-related complications and practical solutions”. Seminars in Interventional Radiology 23 (2006): 165-176.
12. Sauer P., et al. “Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial”. Hepatology 24 (1996): 1433-1436.
13. Eesa M and Clark T. “Transjugular intrahepatic portosystemic shunt: state of the art”. Seminars in Roentgenology 46 (2011): 125-132.
14. Jalan R., et al. “Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage”. Journal of Hepatology 23 (1995): 123-128.
15. Leng X., et al. “Comparison of transjugular intrahepatic portosystemic shunt for treatment of variceal bleeding in patients with cirrhosis with or without spontaneous portosystemic shunt”. European Journal of Gastroenterology and Hepatology 31 (2019): 853-858.